Exact Mass: 492.2525
Exact Mass Matches: 492.2525
Found 500 metabolites which its exact mass value is equals to given mass value 492.2525
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
rac-5,6-Epoxy-retinoyl-beta-D-glucuronide
This compound belongs to the family of Diterpene Glycosides. These are diterpenes in which an isoprene unit is glycosylated.
4-Hydroxyretinoic acid glucuronide
4-Hydroxyretinoic acid glucuronide belongs to the class of organic compounds known as diterpene glycosides. These are diterpenoids in which an isoprene unit is glycosylated.
Bezitramide
N - Nervous system > N02 - Analgesics > N02A - Opioids > N02AC - Diphenylpropylamine derivatives D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent D002491 - Central Nervous System Agents > D000700 - Analgesics
Lurasidone
Vorapaxar
PA(2:0/18:1(12Z)-O(9S,10R))
PA(2:0/18:1(12Z)-O(9S,10R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/18:1(12Z)-O(9S,10R)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 9,10-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(18:1(12Z)-O(9S,10R)/2:0)
PA(18:1(12Z)-O(9S,10R)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:1(12Z)-O(9S,10R)/2:0), in particular, consists of one chain of one 9,10-epoxy-octadecenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(2:0/18:1(9Z)-O(12,13))
PA(2:0/18:1(9Z)-O(12,13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/18:1(9Z)-O(12,13)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 12,13-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(18:1(9Z)-O(12,13)/2:0)
PA(18:1(9Z)-O(12,13)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:1(9Z)-O(12,13)/2:0), in particular, consists of one chain of one 12,13-epoxy-octadecenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
Kushenol B
Kushenol B is a member of flavanones. Kushenol B is a natural product found in Sophora and Sophora flavescens with data available.
Kadlongilactone B
A hexacyclic triterpenoid isolated from the leaves and stems of Kadsura longipedunculata and has been found to exhibit cytotoxicity aganist human tumour cells.
Macaflavanone G
A trihydroxyflavanone that is (2S)-flavanone substituted by hydroxy groups at positions 5, 7 and 4, a prenyl group at position 6 and a (2S)-2-methyl-2-(4-methylpent-3-en-1-yl)tetrahydro-2H-pyran ring fused across positions 2 and 3. Isolated from the leaves of Macaranga tanarius, it exhibits antineoplastic activity.
2,4,6,3-Tetrahydroxy-3-geranyl-6,6-dimethylpyrano[2,3:4,5]dihydrochalcone
Propolin G
(-)-Nymphaeol C|(-)-Nymphaeol-C|5,7,3,4-tetrahydroxy-6-(3,3-dimethylallyl)-2-C-geranylflavanone|5,7,3,4-tetrahydroxy-6-(3,3-dimethylallyl)-2-geranylflavanone|Nymphaeol C|nymphaeol-C|propolin G
(E)-1,3-dihydroxy-6,7-dimethoxy-2-(3-methylbut-2-enyl)-8-(3,7-dimethyl-2,6-octadienyl)xanthone|6-O-methylcowanin
lespeflorin B4
A trihydroxyflavanone that is (2S)-flavanone substituted by hydroxy groups at positions 3, 5, 7 and 4 and prenyl groups at positions 6, 8 and 3. Isolated from the roots of Lespedeza floribunda, it acts as a melanin synthesis inhibitor.
Sanggenol P
5,7,2,4-tetrahydroxyl-6,8,5-tri-(gamma,gamma-dimethylallyl)isoflavanone|6,8,5-tri-(gamma,gamma-dimethylallyl)dalbergioidin|ormosinol
Cys Asp Lys Lys
Cys Lys Asp Lys
Cys Lys Lys Asp
Cys Lys Arg Ser
Cys Lys Ser Arg
Cys Arg Lys Ser
Cys Arg Ser Lys
Cys Ser Lys Arg
Cys Ser Arg Lys
Asp Cys Lys Lys
Asp Phe Ile Val
Asp Phe Leu Val
Asp Phe Val Ile
Asp Phe Val Leu
Asp Ile Phe Val
Asp Ile Val Phe
Asp Lys Cys Lys
Asp Lys Lys Cys
Asp Leu Phe Val
Asp Leu Val Phe
Asp Val Phe Ile
Asp Val Phe Leu
Asp Val Ile Phe
Asp Val Leu Phe
Glu Phe Val Val
Glu Val Phe Val
Glu Val Val Phe
Phe Asp Ile Val
Phe Asp Leu Val
Phe Asp Val Ile
Phe Asp Val Leu
Phe Glu Val Val
Phe Gly Asn Arg
Phe Gly Arg Asn
Phe Ile Asp Val
Phe Ile Val Asp
Phe Leu Asp Val
Phe Leu Val Asp
Phe Met Pro Val
Phe Met Val Pro
Phe Asn Gly Arg
Phe Asn Arg Gly
Phe Pro Met Val
Phe Pro Val Met
Phe Arg Gly Asn
Phe Arg Asn Gly
Phe Val Asp Ile
Phe Val Asp Leu
Phe Val Glu Val
Phe Val Ile Asp
Phe Val Leu Asp
Phe Val Met Pro
Phe Val Pro Met
Phe Val Val Glu
Gly Phe Asn Arg
Gly Phe Arg Asn
Gly Asn Phe Arg
Gly Asn Arg Phe
Gly Arg Phe Asn
Gly Arg Asn Phe
His His Ile Ser
His His Leu Ser
His His Ser Ile
His His Ser Leu
His His Thr Val
His His Val Thr
His Ile His Ser
His Ile Ser His
His Leu His Ser
His Leu Ser His
His Ser His Ile
His Ser His Leu
His Ser Ile His
His Ser Leu His
His Thr His Val
His Thr Val His
His Val His Thr
His Val Thr His
Ile Asp Phe Val
Ile Asp Val Phe
Ile Phe Asp Val
Ile Phe Val Asp
Ile His His Ser
Ile His Ser His
Ile Met Met Val
Ile Met Val Met
Ile Pro Thr Tyr
Ile Pro Tyr Thr
Ile Ser His His
Ile Thr Pro Tyr
Ile Thr Tyr Pro
Ile Val Asp Phe
Ile Val Phe Asp
Ile Val Met Met
Ile Tyr Pro Thr
Ile Tyr Thr Pro
Lys Cys Asp Lys
Lys Cys Lys Asp
Lys Cys Arg Ser
Lys Cys Ser Arg
Lys Asp Cys Lys
Lys Asp Lys Cys
Lys Lys Cys Asp
Lys Lys Asp Cys
Lys Met Asn Thr
Lys Met Gln Ser
Lys Met Ser Gln
Lys Met Thr Asn
Lys Asn Met Thr
Lys Asn Thr Met
Lys Gln Met Ser
Lys Gln Ser Met
Lys Arg Cys Ser
Lys Arg Ser Cys
Lys Ser Cys Arg
Lys Ser Met Gln
Lys Ser Gln Met
Lys Ser Arg Cys
Lys Thr Met Asn
Lys Thr Asn Met
Leu Asp Phe Val
Leu Asp Val Phe
Leu Phe Asp Val
Leu Phe Val Asp
Leu His His Ser
Leu His Ser His
Leu Met Met Val
Leu Met Val Met
Leu Pro Thr Tyr
Leu Pro Tyr Thr
Leu Ser His His
Leu Thr Pro Tyr
Leu Thr Tyr Pro
Leu Val Asp Phe
Leu Val Phe Asp
Leu Val Met Met
Leu Tyr Pro Thr
Leu Tyr Thr Pro
Met Phe Pro Val
Met Phe Val Pro
Met Ile Met Val
Met Ile Val Met
Met Lys Asn Thr
Met Lys Gln Ser
Met Lys Ser Gln
Met Lys Thr Asn
Met Leu Met Val
Met Leu Val Met
Met Met Ile Val
Met Met Leu Val
Met Met Val Ile
Met Met Val Leu
Met Asn Lys Thr
Met Asn Thr Lys
Met Pro Phe Val
Met Pro Val Phe
Met Gln Lys Ser
Met Gln Ser Lys
Met Ser Lys Gln
Met Ser Gln Lys
Met Thr Lys Asn
Met Thr Asn Lys
Met Val Phe Pro
Met Val Ile Met
Met Val Leu Met
Met Val Met Ile
Met Val Met Leu
Met Val Pro Phe
Asn Phe Gly Arg
Asn Phe Arg Gly
Asn Gly Phe Arg
Asn Gly Arg Phe
Asn Lys Met Thr
Asn Lys Thr Met
Asn Met Lys Thr
Asn Met Thr Lys
Asn Arg Phe Gly
Asn Arg Gly Phe
Asn Thr Lys Met
Asn Thr Met Lys
Pro Phe Met Val
Pro Phe Val Met
Pro Ile Thr Tyr
Pro Ile Tyr Thr
Pro Leu Thr Tyr
Pro Leu Tyr Thr
Pro Met Phe Val
Pro Met Val Phe
Pro Thr Ile Tyr
Pro Thr Leu Tyr
Pro Thr Tyr Ile
Pro Thr Tyr Leu
Pro Val Phe Met
Pro Val Met Phe
Pro Tyr Ile Thr
Pro Tyr Leu Thr
Pro Tyr Thr Ile
Pro Tyr Thr Leu
Gln Lys Met Ser
Gln Lys Ser Met
Gln Met Lys Ser
Gln Met Ser Lys
Gln Ser Lys Met
Gln Ser Met Lys
Arg Cys Lys Ser
Arg Cys Ser Lys
Arg Phe Gly Asn
Arg Phe Asn Gly
Arg Gly Phe Asn
Arg Gly Asn Phe
Arg Lys Cys Ser
Arg Lys Ser Cys
Arg Asn Phe Gly
Arg Asn Gly Phe
Arg Ser Cys Lys
Arg Ser Lys Cys
Ser Cys Lys Arg
Ser Cys Arg Lys
Ser His His Ile
Ser His His Leu
Ser His Ile His
Ser His Leu His
Ser Ile His His
Ser Lys Cys Arg
Ser Lys Met Gln
Ser Lys Gln Met
Ser Lys Arg Cys
Ser Leu His His
Ser Met Lys Gln
Ser Met Gln Lys
Ser Gln Lys Met
Ser Gln Met Lys
Ser Arg Cys Lys
Ser Arg Lys Cys
Thr His His Val
Thr His Val His
Thr Ile Pro Tyr
Thr Ile Tyr Pro
Thr Lys Met Asn
Thr Lys Asn Met
Thr Leu Pro Tyr
Thr Leu Tyr Pro
Thr Met Lys Asn
Thr Met Asn Lys
Thr Asn Lys Met
Thr Asn Met Lys
Thr Pro Ile Tyr
Thr Pro Leu Tyr
Thr Pro Tyr Ile
Thr Pro Tyr Leu
Thr Val His His
Thr Tyr Ile Pro
Thr Tyr Leu Pro
Thr Tyr Pro Ile
Thr Tyr Pro Leu
Val Asp Phe Ile
Val Asp Phe Leu
Val Asp Ile Phe
Val Asp Leu Phe
Val Glu Phe Val
Val Glu Val Phe
Val Phe Asp Ile
Val Phe Asp Leu
Val Phe Glu Val
Val Phe Ile Asp
Val Phe Leu Asp
Val Phe Met Pro
Val Phe Pro Met
Val Phe Val Glu
Val His His Thr
Val His Thr His
Val Ile Asp Phe
Val Ile Phe Asp
Val Ile Met Met
Val Leu Asp Phe
Val Leu Phe Asp
Val Leu Met Met
Val Met Phe Pro
Val Met Ile Met
Val Met Leu Met
Val Met Met Ile
Val Met Met Leu
Val Met Pro Phe
Val Pro Phe Met
Val Pro Met Phe
Val Thr His His
Val Val Glu Phe
Val Val Phe Glu
Tyr Ile Pro Thr
Tyr Ile Thr Pro
Tyr Leu Pro Thr
Tyr Leu Thr Pro
Tyr Pro Ile Thr
Tyr Pro Leu Thr
Tyr Pro Thr Ile
Tyr Pro Thr Leu
Tyr Thr Ile Pro
Tyr Thr Leu Pro
Tyr Thr Pro Ile
Tyr Thr Pro Leu
29-demethylgeodisterol-O-sulfite
Vorapaxar
B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AC - Platelet aggregation inhibitors excl. heparin C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors C78274 - Agent Affecting Cardiovascular System COVID info from Guide to PHARMACOLOGY Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
lurasidone
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AE - Indole derivatives D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist
tert-Butyl 4-(5-chloro-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)piperazine-1-carboxylate
ethyl ((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((E)-2-(5-(3-fluorophenyl)pyridin-2-yl)vinyl)-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-yl)carbamate
Bezitramide
N - Nervous system > N02 - Analgesics > N02A - Opioids > N02AC - Diphenylpropylamine derivatives D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent D002491 - Central Nervous System Agents > D000700 - Analgesics
ethyl N-[9-[(E)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethenyl]-1-methyl-3-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-1H-benzo[f][2]benzofuran-6-yl]carbamate
[(2R)-1-acetyloxy-3-phosphonooxypropan-2-yl] (Z)-11-(3-pentyloxiran-2-yl)undec-9-enoate
[(2R)-2-acetyloxy-3-phosphonooxypropyl] (Z)-11-(3-pentyloxiran-2-yl)undec-9-enoate
Nymphaeol C
A tetrahydroxyflavanone that is (2S)-flavanone substituted by hydroxy group at positions 5, 7, 3 and 4, a geranyl group at position 2 and a prenyl group at position 6. Isolated from Macaranga tanarius and propolis collected in Okinawa, it exhibits radical scavenging activity.
schizolaenone B
A tetrahydroxyflavanone that is (2S)-flavanone substituted by hydroxy groups at positions 5, 7, 4 and 5, a geranyl group at position 3 and a prenyl group at position 6. Isolated from Schizolaena hystrix, it exhibits cytotoxicity against ovarian cancer cell line.
Asp-Leu-Phe-Val
A tetrapeptide composed of L-aspartic acid, L-leucine, L-phenylalanine and L-valine joined in sequence by peptide linkages.
3-[[4-(diphenylmethyl)-1-piperazinyl]-oxomethyl]-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazolin-12-one
3-[(1-tert-butyl-5-tetrazolyl)-[2-furanylmethyl(2-oxolanylmethyl)amino]methyl]-6-methoxy-1H-quinolin-2-one
(2S)-2-[(4S,5R)-4-methyl-5-[[methyl(4-oxanylmethyl)amino]methyl]-1,1-dioxo-8-pent-1-ynyl-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
(2R)-2-[(4R,5R)-4-methyl-5-[[methyl(4-oxanylmethyl)amino]methyl]-1,1-dioxo-8-pent-1-ynyl-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
(2S)-2-[(4R,5R)-4-methyl-5-[[methyl(4-oxanylmethyl)amino]methyl]-1,1-dioxo-8-pent-1-ynyl-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
(2R)-2-[(4S,5R)-4-methyl-5-[[methyl(4-oxanylmethyl)amino]methyl]-1,1-dioxo-8-pent-1-ynyl-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
(2S)-2-[(4S,5S)-4-methyl-5-[[methyl(4-oxanylmethyl)amino]methyl]-1,1-dioxo-8-pent-1-ynyl-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
(2R)-2-[(4R,5S)-4-methyl-5-[[methyl(4-oxanylmethyl)amino]methyl]-1,1-dioxo-8-pent-1-ynyl-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
(2R)-2-[(4S,5S)-4-methyl-5-[[methyl(4-oxanylmethyl)amino]methyl]-1,1-dioxo-8-pent-1-ynyl-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
(2S)-2-[(4R,5S)-4-methyl-5-[[methyl(4-oxanylmethyl)amino]methyl]-1,1-dioxo-8-pent-1-ynyl-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
(2S,3S,3aR,9bR)-N1-cyclopentyl-N2-(cyclopropylmethyl)-3-(hydroxymethyl)-6-oxo-7-(5-pyrimidinyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1,2-dicarboxamide
(2R)-2-[(4R,5S)-8-(1-cyclopentenyl)-4-methyl-5-[[methyl(4-oxanylmethyl)amino]methyl]-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
(2S)-2-[(4R,5S)-8-(1-cyclopentenyl)-4-methyl-5-[[methyl(4-oxanylmethyl)amino]methyl]-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
(2R,3R,3aS,9bS)-N1-cyclopentyl-N2-(cyclopropylmethyl)-3-(hydroxymethyl)-6-oxo-7-(5-pyrimidinyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1,2-dicarboxamide
(1S)-1-(hydroxymethyl)-7-methoxy-1-[oxo(2-pyrazinyl)methyl]-N-propan-2-yl-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
1-[(1S)-1-(hydroxymethyl)-7-methoxy-9-methyl-1-[oxo(2-pyridinyl)methyl]-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]yl]-2-methoxyethanone
(2S)-4-[(4R,5S)-5-[[cyclohexylmethyl(methyl)amino]methyl]-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-8-yl]-3-butyn-2-ol
(2R)-2-[(4S,5S)-8-(1-cyclopentenyl)-4-methyl-5-[[methyl(4-oxanylmethyl)amino]methyl]-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
(2S)-2-[(4R,5R)-8-(1-cyclopentenyl)-4-methyl-5-[[methyl(4-oxanylmethyl)amino]methyl]-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
(2S)-2-[(4S,5R)-8-(1-cyclopentenyl)-4-methyl-5-[[methyl(4-oxanylmethyl)amino]methyl]-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
(2S)-2-[(4S,5S)-8-(1-cyclopentenyl)-4-methyl-5-[[methyl(4-oxanylmethyl)amino]methyl]-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
(2R)-2-[(4S,5R)-8-(1-cyclopentenyl)-4-methyl-5-[[methyl(4-oxanylmethyl)amino]methyl]-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
(2R)-2-[(4R,5R)-8-(1-cyclopentenyl)-4-methyl-5-[[methyl(4-oxanylmethyl)amino]methyl]-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
(1R)-2-(cyclopropylmethyl)-N-(3-fluorophenyl)-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
(1S)-2-(cyclopropylmethyl)-N-(3-fluorophenyl)-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
(1R)-1-(hydroxymethyl)-7-methoxy-1-[oxo(2-pyrazinyl)methyl]-N-propan-2-yl-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
1-[(1R)-1-(hydroxymethyl)-7-methoxy-9-methyl-1-[oxo(2-pyridinyl)methyl]-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]yl]-2-methoxyethanone
(2R,3R,3aS,9bS)-1-N-cyclopentyl-3-(hydroxymethyl)-6-oxo-7-[(E)-prop-1-enyl]-2-N-(pyrimidin-4-ylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1,2-dicarboxamide
(2S,3S,3aR,9bR)-1-N-cyclopentyl-3-(hydroxymethyl)-6-oxo-7-[(E)-prop-1-enyl]-2-N-(pyrimidin-4-ylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1,2-dicarboxamide
5',9,9,14,18-pentamethyl-3'h-8,20,24-trioxaspiro[hexacyclo[19.2.1.0²,¹³.0⁴,¹⁰.0¹⁴,²².0¹⁷,²²]tetracosane-19,2'-pyran]-2(13),3,5-triene-6',7-dione
3,8,9-trihydroxy-4-[4-hydroxy-3-(hydroxymethyl)but-2-en-1-yl]-6-methyl-4,7-bis(3-methylbut-2-en-1-yl)anthracen-1-one
(1s,10r,14s,17r,18s,19s,21r,22s)-5',9,9,14,18-pentamethyl-3'h-8,20,24-trioxaspiro[hexacyclo[19.2.1.0²,¹³.0⁴,¹⁰.0¹⁴,²².0¹⁷,²²]tetracosane-19,2'-pyran]-2(13),3,5-triene-6',7-dione
(3ar,6s,6ar,10s,12r,13r,15as)-1,6,12,13-tetrahydroxy-3-(1h-indol-3-ylmethyl)-4,5,10-trimethyl-3h,3ah,6h,6ah,9h,10h,11h,12h,13h,14h-cycloundeca[d]isoindol-15-one
2-[2-(3,7-dimethylocta-2,6-dien-1-yl)-3,4-dihydroxyphenyl]-5,7-dihydroxy-6-(3-methylbut-2-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
(2s)-2-[5-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxyphenyl]-5,7-dihydroxy-8-(3-methylbut-2-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
(1s,1'r,2s,3's,5s,6's,9s,10's,11'r,12r,14s)-2-hydroxy-2,3',11,12'-tetramethyl-6-methylidene-2',8,9'-trioxaspiro[tetracyclo[10.2.1.0¹,¹⁰.0⁵,⁹]pentadecane-14,7'-tetracyclo[9.3.0.0¹,³.0⁶,¹⁰]tetradecane]-10,12'-diene-7,8'-dione
(2s)-5,7-dihydroxy-2-[(2r)-8-hydroxy-2-methyl-2-(4-methylpent-3-en-1-yl)-3,4-dihydro-1-benzopyran-6-yl]-6-(3-methylbut-2-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
(1r,2s,13r,15r,18s,23s,24s)-13-hydroxy-1,6,6,20,24-pentamethyl-7,22-dioxahexacyclo[13.12.0.0²,¹³.0⁵,¹¹.0¹⁶,²⁵.0¹⁸,²³]heptacosa-9,11,16(25),19-tetraene-8,21,26-trione
(10s)-4,10,15-trihydroxy-13-methyl-5,7-bis(3-methylbut-2-en-1-yl)-12-[(3-methylbut-2-en-1-yl)oxy]-9-oxatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,12,14-hexaen-2-one
artemyriantholide a
{"Ingredient_id": "HBIN016967","Ingredient_name": "artemyriantholide a","Alias": "NA","Ingredient_formula": "C30H36O6","Ingredient_Smile": "CC1=CCC23C1C4C(CCC2(O3)C)C5(CC6CC57C(=C6C)C8C(CCC7(C)O)C(=C)C(=O)O8)C(=O)O4","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1803","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
artemyriantholide b
{"Ingredient_id": "HBIN016968","Ingredient_name": "artemyriantholide b","Alias": "NA","Ingredient_formula": "C30H36O6","Ingredient_Smile": "CC1=CCC23C1C4C(CCC2(O3)C)C5(CC6CC57C(=C6C)C8C(CCC7(C)O)C(=C)C(=O)O8)C(=O)O4","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1804","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
artemyriantholide d
{"Ingredient_id": "HBIN016970","Ingredient_name": "artemyriantholide d","Alias": "NA","Ingredient_formula": "C30H36O6","Ingredient_Smile": "CC1=CCC23C1C4C(CCC2(O3)C)C5(CC67C=CC5(C6C8C(CCC7(C)O)C(=C)C(=O)O8)C)C(=O)O4","Ingredient_weight": "492.6 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1806","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "21668651","DrugBank_id": "NA"}